Ambrx Biopharma/AMAM

$27.91

-0.1%
-
1D1W1MYTD1YMAX

About Ambrx Biopharma

Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). It uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.

Ticker

AMAM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel O'Connor

Employees

66

Headquarters

La jolla, United States
Website
ambrx.com

Ambrx Biopharma Metrics

BasicAdvanced
$1.77B
Market cap
-
P/E ratio
-
EPS
-
Beta
-
Dividend rate

What the Analysts think about Ambrx Biopharma

Analyst Ratings

Majority rating from 8 analysts.
Hold

Price Targets

Average projection from 4 analysts.
2.11% upside
High $30.00
Low $28.00
$27.91
Current price
$28.50
Average price target

Ambrx Biopharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-100%
Net income
$-22.9M
28.65%
Profit margin
0%
-100%

Ambrx Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 91.38%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Actual
-$0.35
-$0.37
-
Expected
-$0.09
-$0.19
-$0.39
Surprise
268.98%
91.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell Ambrx Biopharma stock

Buy or sell Ambrx Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing